Exact claim · Version 1 · Reviewed 2026-07-23
“Tirzepatide has established human outcome evidence for defined metabolic indications.”
A verdict on this wording and scope, not a universal grade for Tirzepatide.
01 · Verdict
Supported with scope
Approved product labels and large randomized trials support specific glycemic and weight outcomes in defined populations.
- Evidence basis
- Randomized human outcomes
- Scope
- Mounjaro and Zepbound in the labeled and trial populations, endpoints, comparators, and durations.
- Category
- Clinical outcomes
02 · Primary record
Check the attached evidence
01MOUNJARO (tirzepatide) prescribing informationU.S. Food and Drug Administration · Drug label · 2026
Supports the scoped claim02ZEPBOUND (tirzepatide) prescribing informationU.S. Food and Drug Administration · Drug label · 2026
Supports the scoped claim03Tirzepatide once weekly for the treatment of obesityPubMed · New England Journal of Medicine · Randomized trial · 2022
Supports the scoped claim04Tirzepatide versus semaglutide once weekly in patients with type 2 diabetesPubMed · New England Journal of Medicine · Randomized trial · 2021
Supports the scoped claim
Supports the scoped claim02ZEPBOUND (tirzepatide) prescribing informationU.S. Food and Drug Administration · Drug label · 2026
Supports the scoped claim03Tirzepatide once weekly for the treatment of obesityPubMed · New England Journal of Medicine · Randomized trial · 2022
Supports the scoped claim04Tirzepatide versus semaglutide once weekly in patients with type 2 diabetesPubMed · New England Journal of Medicine · Randomized trial · 2021
Supports the scoped claim
- Editorial review
- Internal editorial review recorded
- Responsible editor
- Anthony Treviso · Founder and responsible editor
- Clinical-review boundary
- Not independently medically reviewed.